Ochre Bio CSO Quin Wills (L) and CEO Jack O'Meara
April 22, 2024 04:20 AM EDTUpdated 07:02 AM
Deals
R&D

Boehringer In­gel­heim inks chron­ic liv­er dis­ease re­search pact with Ochre Bio

Lei Lei Wu

News Reporter

Boehringer In­gel­heim is pay­ing Ochre Bio $35 mil­lion in up­front and near-term pay­ments to dis­cov­er new treat­ments for chron­ic liv­er dis­eases like meta­bol­ic dys­func­tion-as­so­ci­at­ed steato­hep­ati­tis …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

NewAms­ter­dam aces Phase 3 tri­al, but in­vestors are skep­ti­cal

Post-Hoc: RFK vs. Vivek, and the fu­ture of US drug pol­i­cy

FDA up­dates la­bel of 33-year-old can­cer drug with new dose and warn­ing

Pfiz­er part­ners with two more Flag­ship biotechs on obe­si­ty, can­cer

When gen­er­a­tive AI meets the FDA: First dig­i­tal health ad­comm kicks off dis­cus­sion

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times